Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma’s pan-viral ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Here’s what to know about norovirus and where things stand with the development of a stomach-bug vaccine. “Commonly known as the stomach flu, norovirus has been around forever, and has become ...

Canada is just emerging from another winter wave of multiple infectious diseases only for the population to be confronted ...

"We are pleased to initiate a Phase 1 trial for our oral bivalent norovirus vaccine, delivered in a pill formulation, which will seek to demonstrate improved immune responses of our second ...

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma's pan-viral ...

Its initial programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by ...

Among these, we may find a cytomegalovirus (CMV) vaccine, a personalized cancer vaccine, and a norovirus vaccine. All of these programs are involved in phase 3 trials today. The company also is ...

The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives ...

There is currently no vaccine available for norovirus, unlike other common seasonal viruses like the flu, RSV and COVID-19. In October last year, a phase 3 randomised controlled trial of a new ...